MiNK Therapeutics (NASDAQ:INKT) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of MiNK Therapeutics (NASDAQ:INKT) from a hold rating to a sell rating in a report issued on Sunday.

A number of other research analysts also recently weighed in on INKT. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. Zacks Research raised shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Performance

Shares of NASDAQ:INKT opened at $11.80 on Friday. The company has a market capitalization of $55.34 million, a PE ratio of -3.89 and a beta of 0.34. The company has a fifty day moving average of $11.95 and a 200-day moving average of $14.16. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.21. On average, equities analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.